POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: geobee on April 01, 2014, 10:38:01 pm
-
I received this today from Quest, in San Francisco, run by Dr. Jay Lalezari:
"Dear Quest Email Recipients,
We are pleased to announce the opening of a 12 week treatment substitution study that pays $2,000.
Eligible subjects will replace their current ARV therapy for 12 weeks with a once weekly CCR5 Monocolonal Antibody that is administered SQ.
After the 12 week period, subjects resume their prior ARV regimen.
In order to be eligible for the study, you must have:
1) Current T Cell count above 350 (and Never had a T cell count under 200).
2) Current viral load below 50 copies.
3) No Active hepatitis B.
If you are interested or would just like to schedule a visit to come by and chat, please contact Ula at 415-353-0800 or at Ula@Questclinical.com.
With Kind regards,
Dr. Jay
Medical Director,
Quest Research"
-
Thanks.
We only have to know what is the name of this mAb.
Is this the Ibalizumab ?
-
I'm not sure of the name of the mAb. I've put a call into Quest, when they call back I'll post about what I find out.
-
I heard back from Quest. The name is Pro 140 -- below is the company's website.
http://www.cytodyn.com/drug-pipeline/pro-140
You go off your ARVs, get injected once a week for 12 weeks, you go back on meds -- that's the trial.
It's not an attempt at a cure -- it's an entry inhibitor. For people who can't take meds orally or are resistant.